Pfizer Stock Outperforms Broader Market as Q4 Earnings Fall, But 2022 Income Rises
• Pfizer (PFE) stock rose 0.75% on a day the broader market declined, outpacing the S&P 500, Dow, and Nasdaq
• PFE stock is up 3.86% over the past month, exceeding the Medical sector and S&P 500
• PFE's Q4 EPS is expected to fall 54.47% but full-year earnings are forecast to rise 20.11%
• PFE has a Zacks Rank of #3 (Hold) and trades at a lower Forward P/E ratio than its industry average
• The Large Cap Pharmaceuticals industry ranks in the bottom 23% of Zacks industries, underperforming the broader market